Whether surgery can proceed when a fungal infection is present depends on the type of infection, the kind of surgery, and the patient’s overall health. A minor surface infection like athlete’s foot poses different risks than an invasive fungal disease deep in the lungs. In some cases, surgery itself is the treatment for a severe fungal infection that drugs alone cannot clear. The answer, then, is not a blanket yes or no but a judgment call that weighs urgency, location, and individual risk factors.
When Surgery Is the Treatment for the Fungal Infection
The scenario many people picture is an elective procedure being delayed because of an existing infection. But in clinical practice, a large share of surgeries performed alongside fungal infections are done specifically to fight the fungus. Invasive infections caused by Aspergillus or Mucor species can destroy tissue rapidly, and antifungal drugs sometimes cannot reach the infected area well enough on their own. In these situations, surgeons remove the damaged or dead tissue in a procedure called debridement, and antifungal medication serves as a backup rather than the primary weapon.
Mucormycosis, a particularly aggressive infection that can invade the sinuses, eyes, and brain, is a textbook example. Repeated surgical debridement combined with antifungal therapy is considered the standard approach. The surgical goal is to cut away all visibly infected and dead tissue until clean margins are confirmed, sometimes through microscopic examination during the operation itself.
For lung infections caused by Aspergillus, surgery is typically considered when antifungal medication has failed to shrink the lesion, when the infection is getting worse despite treatment, or when serious complications like heavy bleeding have already developed. A multidisciplinary team of infectious disease doctors, surgeons, radiologists, and pharmacists typically evaluates the patient before deciding on an operation.
In a study of pediatric cancer patients with invasive fungal disease, about 80% of surgeries were prompted by the infection progressing or failing to improve with medical treatment alone, while roughly 20% were performed to confirm the diagnosis. The lungs were the most common site of infection, and Aspergillus was the most frequently identified pathogen.
Among adult leukemia patients who underwent surgery to manage invasive fungal infections, the three-month survival rate after the procedure was close to 90%, and roughly two-thirds of patients were alive two years later. Most patients benefited from the surgery. The median wait before they could resume chemotherapy or stem cell transplant was about 25 days.
How Surface Infections Affect Elective Surgery
The more common real-world question is whether something like a toenail fungus or a skin infection could affect a planned joint replacement or other elective procedure. This is where the evidence gets genuinely concerning, even though the infection itself might seem trivial.
A study examining patients undergoing total knee replacement found that those with a superficial fungal infection, whether at the surgical site or elsewhere on the body, had a significantly higher rate of joint infection in the year following surgery compared to patients without any fungal skin condition. The rate of periprosthetic joint infection was about 9% in patients with superficial mycosis versus 0% in those without it. Surprisingly, all of the resulting infections were caused by bacteria, not fungi. The fungal skin condition appeared to make patients more susceptible to bacterial colonization around the surgical site.
This finding matters because it suggests the risk is not limited to the fungus spreading into the wound. A disrupted skin barrier or altered local microbial balance from a fungal infection may invite bacterial pathogens to take hold after surgery. Surgeons who learn of a pre-existing fungal skin infection before an elective procedure may choose to treat the fungal condition first and postpone the operation until it clears.
Who Faces the Highest Risk
Not everyone with a fungal infection faces the same surgical risk. The patients most vulnerable to dangerous outcomes tend to share certain characteristics that weaken their ability to fight off fungal organisms.
- Organ transplant recipients: People who have received a liver, kidney, or other solid organ transplant take immunosuppressive drugs to prevent rejection, and those same drugs suppress the immune defenses that normally keep fungal organisms in check. Liver transplant recipients in particular are considered high risk for invasive Candida and Aspergillus infections.
- Poorly controlled diabetes: High blood sugar impairs the ability of white blood cells to engulf and kill pathogens. It also creates an iron-rich environment that feeds certain fungi. Diabetic ketoacidosis is one of the strongest risk factors for mucormycosis, which can invade the sinuses and orbit with devastating speed.
- Patients on chemotherapy: Cancer treatments that suppress bone marrow reduce the supply of neutrophils, the immune cells that serve as the body’s first line of defense against fungal invaders. Prolonged periods of very low white blood cell counts leave these patients especially exposed.
- Patients on corticosteroids: Long-term or high-dose steroid use dampens the innate immune response. Combined with the immunosuppressants used in transplant settings, steroids create conditions where opportunistic fungi thrive.
- Underweight patients: Research on lung cancer patients undergoing surgery found that those who were underweight and carried certain genetic variants had a substantially elevated risk of developing invasive pulmonary aspergillosis after the procedure.
The susceptibility of transplant recipients and other immunocompromised patients to fungal infections is shaped by multiple overlapping factors: the drugs they take, the state of their immune system, and sometimes even exposures from the organ donor.
Antifungal Drugs and Surgical Medications Can Clash
If you are being treated for a fungal infection with antifungal drugs at the time of surgery, the interaction between those drugs and the medications used during and after the operation is a real concern that your surgical and anesthesia teams need to manage carefully.
Triazole antifungals, a widely used class that includes fluconazole, itraconazole, voriconazole, and posaconazole, interfere with liver enzymes that break down many other drugs. This means they can raise the blood levels of opioid painkillers, sedatives like benzodiazepines, blood thinners, immunosuppressants, corticosteroids, and certain antibiotics. A patient taking voriconazole for a lung infection who then receives a standard dose of a benzodiazepine for sedation could end up far more sedated than expected because the antifungal slows the breakdown of the sedative.
Amphotericin B, an older but still critical antifungal used for severe infections, carries its own set of perioperative issues. Its liposomal formulation is gentler on the kidneys than the original version, but it still demands close monitoring of kidney function and electrolytes like potassium and magnesium. If a patient is dehydrated before surgery, the risk of kidney injury from amphotericin rises, so fluid status needs to be corrected beforehand. Kidney function ideally gets checked daily in patients receiving the drug around the time of an operation.
These interactions do not necessarily prevent surgery, but they add layers of complexity. The surgical team needs a full picture of what antifungals you are taking, for how long, and at what dose so they can adjust anesthetic agents, pain management, and postoperative medications accordingly.
Fungal Infections and Joint Replacements
Fungal infection of a prosthetic joint is uncommon, occurring in roughly 1% to 2% of all joint replacement infections. But when it does happen, it is notoriously difficult to treat. Candida species are the usual culprits, and they form biofilms on the surface of the artificial joint. These biofilms are dense communities of organisms encased in a protective matrix that makes them highly resistant to antifungal drugs circulating in the bloodstream.
Compared to bacterial joint infections, fungal ones have worse outcomes. The preferred treatment for a chronic fungal prosthetic joint infection is a two-stage revision: the infected implant is removed, the patient undergoes a prolonged course of antifungal therapy (often months), and then a new implant is placed once the infection appears to have cleared. Even with this aggressive approach, results tend to be less successful than similar procedures for bacterial infections.
Newer strategies are being explored, including cement beads loaded with antifungal agents placed temporarily in the joint space and agents designed to break apart biofilms. These are still experimental but reflect how challenging the problem remains.
Operating Room Air Quality
Some fungal exposure risk during surgery comes not from the patient but from the environment. Aspergillus spores are ubiquitous in the air, and they can infiltrate operating rooms through ventilation systems, particularly during hospital construction or renovation. High-efficiency particulate air (HEPA) filters can reduce airborne fungal counts by 90% to 95%, bringing Aspergillus levels below a threshold associated with outbreaks.
When ventilation systems malfunction or are poorly maintained, the consequences can be dramatic. One investigation found operating room air contaminated with nearly 200 colony-forming units per cubic meter of Penicillium, a fungal genus, compared to about 15 in the filtered corridor air outside. The contamination was traced to fiberglass lining inside ventilation ducts that had become colonized by both Penicillium and Aspergillus. Decontamination required replacing filters and treating the ductwork with aerosolized chlorine.
For immunocompromised patients, these environmental exposures during surgery can be the difference between an uneventful recovery and a life-threatening invasive infection. Hospitals performing transplant surgery or operating on patients with severely suppressed immune systems typically maintain positive-pressure rooms with HEPA filtration to minimize airborne fungal spore counts.
Preventing Fungal Infections Around Surgery
Preventive antifungal treatment before or during surgery is standard for certain high-risk groups. Based on available evidence, antifungal prophylaxis is considered appropriate for kidney or liver transplant recipients, severely immunocompromised patients undergoing abdominal surgery, patients with perforated ulcers or peritonitis, and patients on peritoneal dialysis who are not responding to antibiotics.
For gastrointestinal surgery specifically, the evidence on routine preventive antifungals is mixed. A randomized trial comparing the antifungal micafungin to placebo in patients undergoing abdominal surgery for intra-abdominal infections found no meaningful difference in the rate of invasive Candida infections between the two groups. The infection rate was about 9% in the placebo group and about 11% in the treatment group. This suggests that blanket antifungal prophylaxis for all abdominal surgery patients does not help and that targeting prevention to the highest-risk individuals makes more sense.
Before elective surgery, treating any active fungal infection and optimizing immune function when possible are the most practical steps. For diabetic patients, bringing blood sugar under better control reduces the favorable conditions that fungi exploit. Correcting nutritional deficiencies and ensuring adequate hydration are also basic but meaningful measures.
Surgical Margins Matter in Fungal Surgery
When surgery is performed to remove a fungal mass, how much tissue the surgeon takes around the visible infection makes a measurable difference in outcomes. In patients undergoing lung surgery for Aspergillus infections, those whose surgical margins just grazed the edge of the fungal mass (tangential margins) had a far higher rate of disease recurrence than those with wider margins of healthy tissue. Every case of recurrence occurred in the tangential margin group. Those patients also had less reduction in their Aspergillus blood test levels afterward, suggesting the infection was not fully cleared.
For rhinocerebral mucormycosis, a similar principle applies. Surgeons continue removing tissue until they can confirm clean margins, sometimes using rapid microscopy or fungal DNA testing during the operation. Once margins are confirmed clear, reconstructive surgery using tissue flaps can be performed safely. The transferred tissue also brings its own blood supply, which helps deliver systemic antifungal drugs to the area.
Telling Fungal Infections Apart From Bacterial Ones After Surgery
One of the trickiest aspects of fungal surgical site infections is that they can look identical to bacterial infections in the early stages. Fever, redness, swelling, and drainage are common to both. The most frequent fungal culprits in surgical site infections are Candida species, followed by Aspergillus and Mucor, and they show up most often after transplant, cardiac, and gastrointestinal surgeries.
Standard blood markers used to detect infection can help but are imperfect. Procalcitonin, a blood test commonly used to flag bacterial sepsis, tends to spike much higher with certain bacterial infections than with fungal ones. In one study, procalcitonin levels in fungal bloodstream infections were comparable to those in infections caused by one class of bacteria, making the two difficult to distinguish on that test alone. Combining multiple markers can improve accuracy, but there is no single blood test that reliably identifies a fungal infection the way cultures and tissue biopsies do.
The difficulty of early diagnosis is a major reason fungal surgical site infections carry higher complication rates. By the time cultures confirm a fungal pathogen, days may have passed during which the patient received only antibacterial drugs that do nothing against fungi. Extended hospital stays, broad-spectrum antibiotic use, and the presence of invasive devices like catheters or shunts all increase the window of vulnerability.
Children and Fungal Surgery
Pediatric patients with blood cancers face many of the same fungal challenges as adults, but their smaller size and developing bodies add complications. In a large review of children with blood cancers who developed invasive fungal disease, 44 out of 70 ultimately required surgical intervention. The lungs were the primary site in about 80% of cases, and Aspergillus was the dominant pathogen in three-quarters of them. Only a small number needed emergency surgery; most operations were planned after medical therapy had stalled.
Preoperative factors that predicted worse surgical outcomes in children included low platelet counts, infection involving multiple lobes of the lung, and centrally located lesions near major airways. Children with lesions closer to the center of the chest were more likely to need blood transfusions during surgery and to experience delays before they could restart their cancer treatment. These findings have pushed some centers toward more detailed preoperative imaging and blood work to identify which children are likely to face a tougher surgical course, so teams can prepare accordingly.